Re: Dislog Magazine

[Guest guest]

Thank you Kathy I am a member at the site and had gone to

check but my Acrobat Reader was being wonky… LOL Still as far as I read that

it doesn’t say they aren’t any good just it’s unknown past

two years on one and that one doctor is uncertain on the other… one could

say worse of LDN seeing it hasn’t even had proper study yet…

But thanks for passing on the type I couldn’t get it

to load for the life of me,

From: Kathy Penrose

[mailto:penrose@...]

Sent: Friday, January 30, 2004

11:15 AM

Cc: Hi everyone

Subject: [low dose naltrexone]

Dislog Magazine

it was

the one with the picture of the nurse on it. I copied the two sections I was

refering to for you.

Ameta-analysis of three clinical studies

of glatiramer acetate has

reported a one-third reduction

in

relapses over the two-year

study period.

The median time to a first

relapse was

322 days with glatiramer

acetate compared

to 219 days with placebo.

( " Median " means that

one-half of the

people had a relapse before

that time

point and one-half had it

after.) Greater

disability and a higher

relapse rate prior

to the study were the best

predictors of

relapse rate while on

treatment. It has not

been determined if a reduction

in

relapse rate lowers the risk

of disability

beyond the first two years of

therapy.

The study was first presented

by Dr.

Jerry Wolinsky and colleagues

at the April

meeting of the American Academy of

Neurology (see the last issue

of Dialog,

vol. 4, no. 2), and was

published in the

August issue of the journal Multiple Sclerosis

Canadian neurologist Dr.

Rice of London, Ontario,

and European

researchers have questioned

whether beta-interferons used to treat

relapsing-remitting MS are effective

after one year of treatment (Lancet, vol.

361, pp. 545-552, 2003).